Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Phase 2 trial more than likely

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon Aug 12, 2021 9:36am

220 Views

Post# 33690937

RE:Phase 2 trial more than likely

That is not my reading.
Everything went fine at 75 mg.

These 3 patients may have had several diagnostic outcomes that could be unrelated to dosage in which case their results can be omitted from the trial results .

So, that is a necessary process which might turn out to be of no concern for the 100 mg dose.

That there were no safety concerns in previous trials suggest that these three are outliers whose response was not dose related..

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles